Primary brain cancer (ICD-10 = C70, C71, C72) is defined as a malignant neoplasm that originates in the central nervous system (CNS), which consists of the brain and spinal cord, including the brain stem (National Cancer Institute, 2021). The American Brain Tumor Association (ABTA) reports that there are over 120 different types of malignant and benign brain tumors (American Brain Tumor Association, 2020). The type and severity of a brain tumor is defined by the cells from which the tumor originated, as well as by the proliferative potential of the abnormal growth. Only malignant tumors are designated as cancer (National Cancer Institute, 2021).
The report includes a 10-year epidemiological forecast for the diagnosed incident cases and five-year diagnosed prevalent cases of brain cancer segmented. The diagnosed incident cases of brain cancer are further segmented by sex, age (all ages), and type (glioblastoma, meningioma, ependymoma, oligodendroglioma, CNS lymphoma, and others). Further, the diagnosed incident cases of glioblastoma are also segmented by grade (low-grade glioma and high-grade glioma), origin (primary and secondary), biomarkers (MGMT unmethylated, MGMT methylated, EGFR VIII positive, and EGFR amplification positive), and mutations (IDH1/IDH2 mutation, TERT promotor mutation, BRAF-V600E mutation, and NTRK mutation).
The following data describes epidemiology of brain cancer. In the 8MM, the publisher epidemiologists forecast an increase in the diagnosed prevalent cases of brain cancer from 121,646 cases in 2020 to 147,148 cases in 2030, at an AGR of 2.10% over the forecast period. The five-year diagnosed prevalent cases of brain cancer in the 8MM are expected to increase from 243,850 cases in 2020 to 303,136 cases in 2030, with an AGR of 2.43% during the forecast period. Brain cancer is known to be more common in men than in women and shows a bimodal distribution, with an increased incidence among children and an increasing incidence with age. This is shown in the publisher’s forecast for the diagnosed incident cases from 2020-2030 in the 8MM.
The Brain Cancer Epidemiology series will allow you to:
The report includes a 10-year epidemiological forecast for the diagnosed incident cases and five-year diagnosed prevalent cases of brain cancer segmented. The diagnosed incident cases of brain cancer are further segmented by sex, age (all ages), and type (glioblastoma, meningioma, ependymoma, oligodendroglioma, CNS lymphoma, and others). Further, the diagnosed incident cases of glioblastoma are also segmented by grade (low-grade glioma and high-grade glioma), origin (primary and secondary), biomarkers (MGMT unmethylated, MGMT methylated, EGFR VIII positive, and EGFR amplification positive), and mutations (IDH1/IDH2 mutation, TERT promotor mutation, BRAF-V600E mutation, and NTRK mutation).
The following data describes epidemiology of brain cancer. In the 8MM, the publisher epidemiologists forecast an increase in the diagnosed prevalent cases of brain cancer from 121,646 cases in 2020 to 147,148 cases in 2030, at an AGR of 2.10% over the forecast period. The five-year diagnosed prevalent cases of brain cancer in the 8MM are expected to increase from 243,850 cases in 2020 to 303,136 cases in 2030, with an AGR of 2.43% during the forecast period. Brain cancer is known to be more common in men than in women and shows a bimodal distribution, with an increased incidence among children and an increasing incidence with age. This is shown in the publisher’s forecast for the diagnosed incident cases from 2020-2030 in the 8MM.
Scope
- The Brain Cancer Epidemiology Report provides an overview of the risk factors and global trends of brain cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China).
- The report includes a 10-year epidemiological forecast for the diagnosed incident cases and five-year diagnosed prevalent cases of brain cancer segmented. The diagnosed incident cases of brain cancer are further segmented by sex, age (all ages), and type (glioblastoma, meningioma, ependymoma, oligodendroglioma, CNS lymphoma, and others). Further, the diagnosed incident cases of glioblastoma are also segmented by grade (low-grade glioma and high-grade glioma), origin (primary and secondary), biomarkers (MGMT unmethylated, MGMT methylated, EGFR VIII positive, and EGFR amplification positive), and mutations (IDH1/IDH2 mutation, TERT promotor mutation, BRAF-V600E mutation, and NTRK mutation). The model associated with this report additionally provides diagnosed incident cases of glioblastoma by recurrence.
- The brain cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to Buy
The Brain Cancer Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global brain cancer market.
- Quantify patient populations in the global brain cancer market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for brain cancer therapeutics in each of the markets covered.
- Understand magnitude of brain cancer population by subtype, digital vasculopathy, and other internal organ involvement.
Table of Contents
1 Brain Cancer: Executive Summary
2 Epidemiology
3 Appendix
List of Tables
List of Figures
